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Abstract
The Ink4a/Arf/Ink4b locus plays a critical role in both cellular senescence and tumorigenesis. 
Jhdm1b/Kdm2b/Fbxl10, the mammalian paralogue of the histone demethylase Jhdm1a/Kdm2a/
Fbxl11, has been implicated in cell cycle regulation and tumorigenesis. In this report, we 
demonstrate that Jhdm1b is an H3K36 demethylase. Knockdown of Jhdm1b in primary MEFs 
inhibits cell proliferation and induces cellular senescence in a pRb and p53 pathway-dependent 
manner. Importantly, the effect of Jhdm1b on cell proliferation and cellular senescence is 
mediated through de-repression of p15Ink4b as loss of p15Ink4b function rescues cell proliferation 
defects in Jhdm1b knockdown cells. Chromatin immunoprecipitation on ectopically expressed 
Jhdm1b demonstrates that Jhdm1b targets the p15Ink4b locus and regulates its expression in an 
enzymatic activity-dependent manner. Alteration of Jhdm1b level affects Ras-induced neoplastic 
transformation. Collectively, our results indicate that Jhdm1b is an H3K36 demethylase that 
regulates cell proliferation and senescence through p15Ink4b.
Introduction
The Ink4a/Arf/Ink4b locus encodes three critical cell cycle inhibitors including p16Ink4a, 
p15Ink4b and Arf (p14 in human and p19 in mouse). The two members of the Ink4 protein 
family inhibit the binding of D-type cyclins to cyclin dependent kinase 4 and 6 (Cdk4/6), 
inhibiting the phosphorylation of retinoblastoma (Rb) family proteins and preventing G1/S 
phase transition in cells. The Arf protein, which shares two common p16Ink4a exons but 
contains a distinct open reading frame, is able to activate the p53 pathway through 
sequestration of the p53 negative regulator Mdm2 (reviewed in1,2).
The Ink4a/Arf/Ink4b locus plays a critical role in determining cellular response to oncogenic 
signals. In normal cells, inappropriate oncogenic stimulation activates this locus and leads to 
cellular senescence. However, dysregulation of this locus can facilitate tumorigenesis 
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through multiple oncogenic signaling pathways. The importance of this locus in cellular 
defense against tumorigenesis is further supported by evidence that Ink4a/Arf/Ink4b is 
frequently deleted or mutated in a variety of human primary tumors3–6. In addition, 
combined deletion of Ink4a/Arf with Ink4b in mice results in a broader spectrum of tumors 
compared to mice with individual genetic deletions indicating that genes in this locus work 
synergistically to prevent tumor development and that p15Ink4b is a critical tumor suppressor 
in the absence of p16Ink4a 7. Since this locus controls both cellular senescence and 
tumorigenesis, tight regulation is crucial under physiological conditions. Although many 
oncoproteins and Polycomb group proteins have been shown to regulate Ink4a/Arf 
expression8,9, the mechanism that controls p15Ink4b expression remains unclear.
The JmjC-domain containing histone demethylase 1b (Jhdm1b) is a paralogue of the first 
identified histone lysine demethylase, Jhdm1a, which targets H3K36 for demethylation10. 
This fact, as well as their high homology within the catalytic JmjC domain (79%), led us to 
predict that the demethylase activity against the H3K36 methyl group is conserved between 
both paralogues (Supplementary Fig. 1). However, in a recent report Jhdm1b was implicated 
in the demethylation of H3K4me3 in vivo11. In addition, the reported biological functions of 
this protein are also controversial. Although two groups have identified Jhdm1b as a hotspot 
for proviral insertion in murine tumors generated by random MMLV mutagenesis, the locus 
has paradoxically been identified as an oncogene and a tumor suppressor depending on the 
screen and functional studies used12,13. In addition, subsequent studies have reported that 
Jhdm1b was a negative regulator of c-Jun14 or rRNA genes11, further implicating Jhdm1b 
in tumor suppression.
In an effort to resolve these apparent discrepancies, we set out to use methods well 
established in our previous studies to characterize the biochemical properties as well as 
biological function of Jhdm1b using primary MEF cells, which maintain normal cell cycle 
regulatory pathways, to study protein function. We report here that Jhdm1b is an H3K36-
specific histone demethylase that functions to promote cellular proliferation and inhibit 
cellular senescence through the silencing of the p15Ink4b tumor suppressor gene.
Results
Jhdm1b is an H3K36me2-specific demethylase
In an effort to explain the difference between activity prediction based on domain homology 
and reported in vivo substrate specificity11, we first investigated the in vitro and in vivo 
catalytic activity of Jhdm1b. To this end, recombinant protein was flag-affinity purified 
from baculovirus-infected Sf9 cells (Supplementary Fig. 2a), and subjected to an histone 
demethylase assay by measuring radioactive formaldehyde release10. Results shown in 
Figure 1a demonstrate that, of all the substrates tested, only the H3K36-specific SET2 
labeled histone substrate can be demethylated by Jhdm1b, indicating that as predicted 
Jhdm1b has a similar substrate specificity to JHDM1A10.
Since the protein was implicated in the demethylation of H3K4me3 in vivo11, we tested the 
capacity of Jhdm1b to demethylate H3K4me3 in vitro. To this end, we purified a new batch 
of wild-type Jhdm1b along with a mutant Jhdm1b (H211A) predicted to kill the enzymatic 
He et al. Page 2













activity (Supplementary Fig. 2b). As controls, we also purified the H3K36me2-specific 
demethylase, JHDM1A10, and the H3K4me3-specific demethylase, RBP215. Incubation of 
these proteins with SET2-labeled histone substrate confirmed efficient formaldehyde release 
for JHDM1A and Jhdm1b, but not Jhdm1b (H211A) (Fig. 1b). In addition, Jhdm1b 
exhibited about one third the activity of JHDM1A when equivalent amount of proteins were 
assayed. Furthermore, incubation of these proteins with substrate labeled by a mutated form 
of the SET7, SET7 (Y245A), which generates K4me2 and K4me316, did not show efficient 
release of formaldehyde above background. However, incubation of RBP2 with the same 
substrate resulted in formaldehyde release (Fig. 1b), demonstrating that Jhdm1b has no 
H3K4me3 demethylase activity under the assay conditions.
To further define the substrate specificity of Jhdm1b, we incubated the protein with core 
histones purified from HeLa cells and analyzed the product by Western blot using 
methylation state-specific antibodies. These experiments demonstrate that Jhdm1b, like its 
paralogue, JHDM1A, can specifically demethylate H3K36me2 and H3K36me1 histone 
substrates (Fig. 1c). However, it does not alter H3K4 methylation levels (Fig. 1c).
To characterize the substrate specificity of Jhdm1b in vivo, we utilized HEK293 cells 
selected for adherence (AD293) and overexpressed Jhdm1b and Jhdm1b (H211A) via 
retroviral infection. Quantitative reverse transcriptase PCR (qRT-PCR) verified similar 
levels of stable expression of wild-type and the mutant Jhdm1b (Fig. 1d). Western blot 
analysis demonstrated that overexpression of wild-type, but not the mutant, Jhdm1b resulted 
in marked decrease of H3K36me2 levels (Fig. 1e). Although a small decrease in 
H3K36me3, as well as H3K4me3 was observed, the minor decrease did not rely on a 
functional JmjC domain as it can also be seen in the cells over expressing the catalytic 
mutant. Given that overexpression of Jhdm1b in HeLa cells was previously reported to 
result in the decrease of H3K4me3 levels11, we overexpressed Jhdm1b in HeLa cells by 
lentiviral infection. Western blot analysis of the histones purified from the infected HeLa 
cells confirmed our observation in the HEK293 cells (Supplementary Fig. 3a). Taken 
together, our results indicate that Jhdm1b is an H3K36 rather than H3K4-specific 
demethylase.
Jhdm1b knockdown inhibits cell proliferation and induces senescence
We next explored the function of Jhdm1b in primary cells. Given that previous analyses of 
Jhdm1b tumor suppressor function had been carried out in transformed or immortalized cell 
lines, we postulated that the paradoxical conclusions regarding the role of Jhdm1b in cancer 
might be due to the many genetic alterations necessary for the establishment of these cell 
lines. We therefore designed an shRNA that can target all three murine isoforms of Jhdm1b 
and introduced it into primary mouse embryonic fibroblast (MEF) cells by lentiviral 
infection (Jhdm1b KD). After selection, the knockdown efficiency (90%) was verified by 
qRT-PCR (Fig. 2a). Interestingly, stable knockdown of Jhdm1b resulted in a substantial 
decrease in cell proliferation (Fig. 2b), a phenotype reminiscent of that displayed by MEF 
cells with reduced levels of the Polycomb group protein Ring1b20,21. Based on this 
observation, shRNA directed against Ring1b was introduced into MEF cells (Ring1b KD), 
and knockdown efficiency was determined to be 90% by qRT-PCR (Fig. 2a). Furthermore, 
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knockdown of Jhdm1b had no substantial effect on Ring1b levels and vice versa (Fig. 2a). 
Comparison of the cell proliferation levels of Ring1b KD, Jhdm1b KD, and control cells 
confirmed Ring1b’s drastic effects on cell proliferation and indicated that Jhdm1b 
knockdown, while drastic, did not achieve the same level of cell growth inhibition as that of 
Ring1b knockdown (Fig. 2b). BrdU pulse labeling followed by flow cytometry analysis 
revealed that Jhdm1b KD resulted in a 2-fold reduction in the number of cells in S-phase as 
compared to control MEFs, while a 4-fold reduction is observed in the Ring1b KD cells 
(Fig. 2c). In addition, Ring1b has been demonstrated to play an important role in regulating 
cellular senescence as a component of the Polycomb repressive complex 1 (PRC1) which 
enacts negative regulation of the p16Ink4a locus20,22. To investigate whether Jhdm1b KD 
also contributes to pre-mature cellular senescence, Ring1b and Jhdm1b KD MEFs were 
analyzed for the presence of senescence-associated β-galactosidase (SA-β-galactosidase) at 
different passages. While only very few cells stained positive for SA-β-galactosidase in 
control MEFs at passage 5, Jhdm1b KD MEFs underwent cellular senescence at a markedly 
increased rate (Fig. 2d) while Ring1b knockdown had the most drastic ability to induce 
senescence. Taken together, these results suggest that Jhdm1b is involved in the positive 
regulation of cell cycle and negative regulation of passage-dependant cellular senescence.
Jhdm1b regulates cell proliferation through p15Ink4b
Cellular proliferation and senescence is tightly regulated through the p53 and pRb pathways, 
and both of these cellular pathways can be inhibited by the introduction of SV40 T antigen 
into primary cells23. To determine whether the function of Jhdm1b in cell proliferation and 
senescence is pRb and p53 dependent, we inactivated both pathways by retroviral expression 
of SV40 large T antigen in MEFs and then subjected the cells to Jhdm1b knockdown. 
Results shown in Supplementary Figure 4a demonstrate that knockdown of Jhdm1b does not 
alter the cellular proliferation of MEF cells when the p53 and pRb pathways are blocked by 
the SV40 large T antigen (Supplementary Fig. 4a). Consistent with this result, the 
percentage of S-phase cells, as indicated by BrdU incorporation, is not altered by Jhdm1b 
knockdown under these conditions (Supplementary Fig. 4b). In addition, Jhdm1b 
knockdown induced cellular senescence, as assessed by the appearance of SA-β-
galactosidase staining, was also blocked in SV40 large T antigen transduced cells 
(Supplementary Fig. 4c). Collectively, these data suggest that Jhdm1b’s pro-growth and 
anti-senescence properties act upstream of these two pathways.
Previous studies have identified a number of genes whose expression is linked to Rb 
regulated cellular senescence and p53-dependant apoptosis24. These genes include members 
of the Ink4a/Arf/Ink4b tumor suppressor locus, p18 (also known as Ink4c), and the cell cycle 
regulators p27 (also known as Cdkn1b) and p21. To determine whether loss of Jhdm1b 
function affected expression of any of these genes, we performed qRT-PCR in control, 
Jhdm1b KD, and Ring1b KD cells. Results shown in Fig. 3a demonstrate that Jhdm1b KD 
resulted in a marked upregulation of p15Ink4b. In agreement with the crucial role of Ring1b 
in the PRC1 complex, Ring1b KD resulted in a substantial upregulation of p16Ink4a 20,22. In 
addition, we also observed a marked increase in p15Ink4b mRNA levels. The effect of 
Jhdm1b and Ring1b KD on p15Ink4b and p16Ink4a levels was also confirmed by Western blot 
(Fig. 3b). These data are consistent with the observation that the p16Ink4a protein has a more 
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potent inhibitory effect on cell proliferation, as well as the notion that p15Ink4b functions to 
back-up the function of p16Ink4a 7. Importantly, similar to Ring1b KD, the expression of 
p21, a p53 pathway target gene, was not altered by Jhdm1b KD (Fig. 3a). To analyze 
whether p15Ink4b is a key mediator of Jhdm1b’s function in cellular proliferation, we derived 
primary MEFs from p15Ink4b null mice25 and performed knockdown of Jhdm1b or Ring1b. 
Results shown in Figure 3c and 3d demonstrate that loss of p15Ink4b function could largely 
rescue the slow proliferation and low BrdU incorporation caused by Jhdm1b knockdown. 
Thus, we conclude that Jhdm1b regulates cellular proliferation and senescence by negatively 
regulating the expression of the p15Ink4b tumor suppressor gene in primary cells.
Jhdm1b regulates p15Ink4b expression through H3K36 demethylation
H3K36 methylation, which has been linked to active gene transcription in organisms from 
yeast to humans, is present within the coding regions of genes being actively transcribed, 
and tends to peak towards the 3’ end of transcribed regions25–28. The mechanism by which 
high levels of H3K36me2 are excluded from the promoter of active genes, as well as the 
functional significance of this observation is still not clear in higher eukaryotes. However, it 
has been demonstrated that SET2 association with elongating RNAPII is at least partly 
responsible for this phenomenon in yeast27. To investigate whether the demethylase activity 
of Jhdm1b directly contributes to p15Ink4b regulation and cellular proliferation, we 
attempted to rescue the Jhdm1b KD MEFs with siRNA resistant wild-type F-Jhdm1b as well 
as catalytically deficient mutant, F-Jhdm1b (H211A). After confirming equal expression of 
the rescue constructs (Supplementary Fig. 5), we analyzed their effects on cellular 
proliferation. Results shown in Figure 4a demonstrate that re-introduction of wild-type 
Jhdm1b rescued the growth defects, while re-introduction of the catalytic-defective mutant 
did not. In addition, re-introduction of wild-type Jhdm1b, but not the catalytic mutant, 
restored p15Ink4b expression to control levels (Fig. 4b). Thus, both normal cell proliferation 
and p15Ink4b repression depends on the demethylase activity of Jhdm1b.
Having established that transcriptional repression of p15Ink4b depends on the H3K36-
demethylase activity of Jhdm1b, we used ChIP assays to decipher whether p15Ink4b is a 
direct target of Jhdm1b. Because none of the available Jhdm1b antibodies worked in 
immunoprecipitation in our hands, we resolved to retrovirally express F-Jhdm1b in primary 
MEF cells and performed ChIP assays using Flag antibodies. F-Jhdm1b was found to be 
specifically enriched 3-fold above background in regions just upstream (amplicon 1) and 
surrounding the transcription start site (amplicon 2) of p15Ink4b when compared with mock 
infected cells (Fig. 4c, d). However, the protein was not enriched within the p15Ink4b intron 
(amplicon 3) (Fig. 4c, d). ChIP analysis of H3K36me2 levels at these same regions in 
Jhdm1b KD and control cells revealed that KD of Jhdm1b resulted in an increase in the 
H3K36me2 levels across the locus when compared to control cells (Fig. 4e), suggesting that 
Jhdm1b might also play an active role in the demethylation of H3K36me2 downstream of 
the transcription start site. However, it has not escaped our attention that increased 
transcription of the gene may itself contribute to increases in H3K36me2 within the coding 
region. Furthermore, rescue of the KD by wild-type Jhdm1b resulted in H3K36me2 levels 
below those of control cells (Fig. 4e). In addition, H3K36me2 levels within the Gapdh locus 
were unchanged for all samples (data not shown). Taken together, these data suggest that 
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p15Ink4b is a direct Jhdm1b target and that Jhdm1b regulates p15Ink4b expression through 
active demethylation of H3K36.
Jhdm1b cooperates with Ras to induce oncogenic transformation
All of the data presented above indicates that Jhdm1b functions as a proto-oncogene through 
its ability to repress transcription of the p15Ink4b locus. In an effort to further establish the 
oncogenic potential of Jhdm1b, we assessed the contribution of the protein to colony 
formation using knockdown or overexpression in p53 null MEFs followed by superinfection 
of retroviral H-Ras12V virus. Results of soft-agar colony formation analysis indicate that 
co-expression of RAS and Jhdm1b in p53 null MEF cells results in an increase in Ras 
induced oncogenic transformation (Fig. 5a). Conversely, knockdown of Jhdm1b inhibited 
Ras-induced colony formation (Fig. 5b). Together these data support the notion that Jhdm1b 
acts as a proto-oncogene in primary fibroblast cells.
Discussion
In this report, we demonstrate that Jhdm1b, like its paralogue Jhdm1a, functions as an 
H3K36 demethylase in vitro and in vivo. Recombinant Jhdm1b purified from baculovirus 
infected Sf9 cells demethylates H3K36me2 in vitro in a radioactive formaldehyde release 
assay and in histone Western blot analysis (Fig. 1) and Western blotting and ChIP analysis 
indicate that overexpression of Jhdm1b results in global H3K36me2 demethylation (Fig. 1e), 
as well as gene-specific H3K36me2 demethylation (Fig. 4) in different cell types including 
HeLa and HEK293 cells (Supplementary Fig. 3a). In addition, the previously suggested 
nucleolar staining pattern of Jhdm1b could not be observed in either HeLa cells11 
(Supplementary Fig. 3b), or AD293 cells (Supplementary Fig. 5b).
In addition to the substrate specificity of Jhdm1b, its role in tumorigenesis has also been a 
point of contention. One of the earliest reports of Jhdm1b function came out of a genetic 
screen for tumor suppressor genes in mouse lymphomas13. The authors identified several 
bi-allelic retroviral insertion events at the Jhdm1b locus when several of the induced 
lymphomas were analyzed. However, further analysis of additional tumor samples revealed 
locus insertion that left the Jhdm1b coding region intact. This leaves open the possibility that 
the tumor manifesting retroviral insertions could either activate or suppresses Jhdm1b 
function. Therefore, the potential of Jhdm1b to serve as an oncogene or tumor suppressor 
was not resolved in this study. In addition some indirect evidence suggested Jhdm1b may act 
as a tumor suppressor, including a link to the negative regulation of c-Jun14, as well as a 
description of its role in the negative regulation of rRNA genes11. However, these 
experiments were carried out in various cell lines in which critical pathways important for 
cellular senescence and tumorigenesis (such as Ink4a/Arf/Ink4b) are also disrupted. Thus 
further evidence would be required to support the relevance of previously identified gene 
targets in a normal context. Arecent report that screened 44 random MMLV induced T cell 
lymphomas identified the Jhdm1b locus as an insertion hotspot12. This study revealed 
multiple, orientated provirus insertions upstream of the canonical Jhdm1b promoter and 
further implicated a role for Jhdm1b overexpression in the immortalization of primary MEF 
cells. In this study, we provide several lines of evidence that support Jhdm1b may indeed be 
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a proto-oncogene. First, we demonstrate in primary MEFs that knockdown of Jhdm1b 
resulted in cell proliferation defects and increased senescence (Fig. 2). Furthermore, we 
demonstrate that Jhdm1b contributes to the regulation of cell proliferation and senescence 
by directly repressing the expression of the p15Ink4b tumor suppressor (Fig. 3 and Fig 4). 
Importantly, p15Ink4b appears to be a major target that mediates Jhdm1b function in cellular 
proliferation since loss of p15Ink4b function can largely rescue the Jhdm1b knockdown 
effects (Fig. 4). Finally, Jhdm1b can cooperate with Ras to transform primary MEF cells 
(Fig. 5). Therefore, we conclude that Jhdm1b is indeed a proto-oncogene which functions at 
least partially by controlling the expression of the p15Ink4b tumor suppressor through 
removal of H3K36me2.
Methods
Cloning, cell line generation
All of the cell lines used in this study were maintained in Dulbeccos’s modified Eagle’s 
medium supplemented with 10% (v/v) fetal bovine serum and 1% (v/v) penicillin/
streptomycin. Primary MEFs harvested from day 13.5 C57BL/6 and p15Ink4b null mouse 
embryos were plated into a P75 flask. The confluent cells were frozen down and considered 
passage 1. The cells were split at 1:5 for each passage. Cell growth was measured by plating 
5×105 MEFs on a 100mm plate in triplicate for each group. The cell number was counted 
using a hemocytometer at the time points indicated. Selection and stable maintenance of 
exogenous plasmids was accomplished in the presence of either 1µg ml−1 (AD293 cells) or 
4µg ml−1 (MEF cells) puromycin. PCR amplification of an EST clone corresponding to full 
length Jhdm1B (NM_001003953) was cloned into a modified pFastBacHT B vector 
(Invitrogen) containing an N terminal flag epitope tag for baculovirus generation as per 
manufacturer’s protocol (Invitrogen). Full length Jhdm1B was subcloned into pMSCVpuro 
vector (Clontech) for stable cell line generation using the manufacturer’s protocol. Jhdm1b 
(H211A) mutant was generated by employing overlapping PCR/subcloning. Stable 
knockdown was achieved using a lentiviral system obtained from the NIH AIDS Research 
and Reference Reagent Program. The mouse U6 promoter was cloned from mouse genomic 
DNA and inserted into the NotI site of pTY-EF1a-nLacZ. For the LV-U6 shRNA-Pgk-Pac 
construct, the Pgk-Pac cassette at NotI/EcoRI sites replaced the EF1a-nLacZ cassette. The 
hairpin RNA targeting Jhdm1b (5’-GCTCCAACTCAGTTACTGT-3’), Ring1b (5’-
GCAGTACACCATTTACATA-3’) and control (5’-GTTCAGATGTGCGGCGAGT-3’) 
were cloned into BBSI/HindIII sties under the U6 promoter 29. To generate wild type and 
mutant Jhdm1b (H211A) rescue constructs, the siRNA target site of Jhdm1b was mutated to 
ATTGCAGTTGAGTTACTGT by PCR mutagenesis. The siRNA resistant wild type and 
mutant Jhdm1b cDNAs were PCR amplified and cloned into either SpeI/EcoRI site of LV 
vector or NotI/XbaI of RV vector.
In vitro histone demethylase formaldehyde release assay
Histone substrates were radiolabeled and formaldehyde release assays were performed as 
previously described10,30. Unless otherwise stated, 5µg of Flag purified recombinant 
protein was incubated in the presence of labeled substrate corresponding to 60,000 input 
counts and demethylase buffer (50 mM HEPES-KOH (pH 8.0), 70 mM Fe(NH4)2(SO4)2, 1 
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mM α-ketoglutarate, 2 mM ascorbate) for one hour at 37°C. Released, labeled formaldehyde 
was extracted using a modified NASH technique and subjected to scintillation counting. 
Data is presented as counts per minute in the extracted sample.
Western blot analysis and immunostaining
Total protein was extracted by RIPA buffer. Purified native histones from HeLa cells or acid 
extracted histones from the indicated cell lines were prepared as previously described31. 
Antibodies against specific methylation states were used at dilutions ranging from 1:250 – 
1:1000: H3K36me1(Abcam 9048), H3K36me210 H3K36me3(Abcam 9050), 
H3K4me1(Abcam 8895), H3K4me2 (Abcam 7766), H3K4me3(Abcam 8580). Blots were 
normalized using an antibody against pan H3 (Abcam 1791). Anti-p21(Santa Cruz SC-397), 
anti-p15Ink4b (Cell Signaling 4822), and anti-p16Ink4a (Santa Cruz SC-1207) were used at 
dilution of 1:1000 for Western Blot. Indirect immunostaining was carried out using primary 
MEFs and Hela cells. The cells were plated onto cover slips in 6 well plates after LV 
transduction, fixed 48 hours post transduction for 20 min in 4% (w/v) paraformaldehyde, 
washed with three times with PBS, and subsequently permeabilized for 20 min in 0.5% (v/v) 
Triton-X-100/PBS. Permeablized cells were blocked in 3% (w/v) BSA/PBS for 30min and 
incubated with Flag monoclonal M2 antibody (Sigma) at 1:1000 dilution in a humidified 
chamber for 3 hours. After incubation, cells were washed 3 times and incubated with FITC 
or Rhodamine conjugated secondary antibodies (Jackson ImmunoResearch Laboratories) at 
dilution of 1:500. Cells were washed twice with PBS, stained with 4,6-diamidino-2-
phenylindole dihydrochloride (DAPI), and mounted on glass slides in fluorescence 
mounting medium (DAKO). Slides were analyzed on an Axiovert 200 fluorescent 
microscope (Zeiss).
BrdU incorporation and cycle cycle analysis
MEFs were grown in the presence of 10 µM BrdU for 60min. The cells were harvested and 
fixed overnight using 75% ethanol. Fixed cells were stained with FITC conjugated mouse 
anti-BrdU antibody (BD biosciences, 347583) and propidium iodide. The stained cells were 
analyzed by flow cytometry (BD FACSCalibur) and data was analyzed using WinMDI 
version 2.9 (TSRI flowcytometry Software).
Senescence associated-β-galactosidase assay
Cells were washed twice with PBS and immersed in fixation buffer (2% (w/v) 
formaldehyde, 0.2% (w/v) glutaraldehyde in PBS) for 10 min. After two additional PBS 
washes the cells were allowed to stain overnight in staining solution (40 mM citric acid/
sodium phosphate pH 6.0, 150 mM NaCl, 2.0 mM MgCl2, 1 mg ml−1 x-gal).
Reverse transcription / qPCR
RNA was extracted and purified from cell lines using Qiashredder (Qiagen) and RNeasy 
(Qiagen) spin columns; DNase treated (Promega RQ1 Dnase) and cleaned up using Qiagen 
RNeasy column (Qiagen). 1µg of RNA was subjected to reverse transcription using random 
primers (Promega) and Improm-II reverse transcription kit (Promega). cDNA levels were 
assayed via Real time PCR using SYBR GreenER (Invitrogen) and analyzed on an ABI 
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7300 Real Time PCR System with SDS software version 1.3.1. qRT-PCR primer sequences 
are available in Supplementary Table 1.
ChIP assay
ChIP assays employing flag-antibody were carried out as previously reported32 with the 
following modifications: 20µl of M2 agarose (Sigma) was used in the immunoprecipitation 
and chromatin-bound beads were washed three times each in TSEI (0.1% [w/v] SDS, 1% 
[v/v] Triton-X-100, 2 mM EDTA, 150 mM NaCl, 20 mM Tris [pH 8.1]) TSEII (0.1% [w/v] 
SDS, 1% [v/v] Triton-X-100, 2mM EDTA, 500 mM NaCl, 20 mM Tris [pH 8.1]) and 
TSEIII (0.25M LiCl, 1% [v/v] NP-40, 1% [w/v] deoxycholate, 1mM EDTA, 10mM Tris 
[pH 8.1]) followed by two washes in TE. Histone modification ChIPs were carried out as 
previously reported33. ChIP DNA was analyzed via qPCR and data are presented as 
percentage of input as determined using Applied Biosystems’s SDS software Absolute 
Quantification protocol. Primer sequences are available in Supplementary Table 1.
Soft agar colony assay
p53 null MEFs were transduced with different LVs. 48 hours after transduction, the cells 
were superinfected with retroviral H-Ras12V virus. 5000 cells were mixed in the 0.35% 
(w/v) top agar and plated onto 0.5% (w/v) basal agar. 14 days after plating, the cells were 
stained with 0.005% (w/v) crystal violet and colony number was counted.
Standard error reporting
All in vitro formaldehyde release assays and cell based assays were performed in triplicate 
and error bars represent the standard deviation of three independent experiments. ChIP 
assays and qRT-PCR experiments were repeated at least twice and data is reported for one 
of the biological replicates. Error bars represent the standard deviation of three qPCR 
reactions as determined by SDS 1.3.1 software (Applied Biosystems). Soft agar colony 
assays were performed and error bars represent the standard deviation of large colony 
numbers between three separate plating replicates.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Jhdm1b is an H3K36-specific demethylase in vitro and in vivo
(a) In vitro formaldehyde release assay using histone substrates generated with the indicated 
methyltransferases and incubated with either recombinant Flag-Jhdm1b (empty bars) or no 
enzyme control (black bars). (b) In vitro formaldehyde release assay using recombinant 
Jhdm1b, Jhdm1b(H211A), JHDM1A and RBP2 incubated with H3K36-methylated (empty 
bars) or H3K4-methylated (black bars) substrates generated with SET2 or SET7(Y245A) 
methyltransferase, respectively. (c) HeLa cell core histones were incubated in the presence 
(+) or absence (−) of recombinant Jhdm1b. The resulting reaction was subjected to Western 
blotting with the indicated modification state-specific antibodies. (d) Jhdm1b mRNA levels 
from AD293 cells stably over-expressing F-Jhdm1b, F-Jhdm1b(H211A), or empty vector 
control cells. Samples were normalized relative to Gapdh and the Jhdm1b expression level 
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in the empty vector control cells was arbitrarily set to 1. (e) Acid extracted histones were 
prepared from AD293 cells stably overexpressing F-Jhdm1b or F-Jhdm1b(H211A) and 
subjected to Western blotting using the indicated methyl-state specific histone antibodies. 
All error bars represent s.d. (n=3).
He et al. Page 13













Figure 2. Jhdm1b knockdown in primary MEFs inhibits cell proliferation and induces cellular 
senescence
(a) Primary MEFs at passage 1 were transduced with lentiviral control (black bars), Jhdm1b 
(Jhdm1b KD, grey bars) or Ring1b (Ring1b KD, empty bars) shRNA and further selected by 
puromycin for 48 hours. mRNA levels were determined by quantitative real-time PCR 
(qRT-PCR). Samples were normalized against levels of Gapdh. The Jhdm1b or Ring1b 
expression level in empty vector control cells was arbitrarily set to 1. (b) Primary MEF cells 
transduced at passage 1 with lentiviral control (diamonds), Jhdm1b (Jhdm1b KD, squares), 
and Ring1b (Ring1b KD, triangles) shRNA and further selected by puromycin for 48 hours. 
5×105 cells were plated and cell number was counted at different time points using a 
hemocytometer. (c) Primary MEFs were prepared as in (b), pulse labeled with BrdU and 
stained with PI and FITC conjugated anti-BrdU antibody. The percentage of BrdU positive 
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cells was determined by flow cytometry for control (black bars), Jhdm1b KD (grey bars) and 
Ring1b KD (empty bars). (d) Cells prepared as in (b) were split at 1:5 for 5 passages and 
senescence associated β-galactosidase activity at pH 6.0 was determined by cellular staining. 
Data is presented for passage 1 (P1) and passage 5 (P5) cells. All error bars represent s.d. 
(n=3).
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Figure 3. Jhdm1b regulates cell proliferation through p15Ink4b
(a) Primary MEFs at passage 1 were transduced with lentiviral control (black bars), Jhdm1b 
(Jhdm1b KD, grey bars) and Ring1b (Ring1b KD, white bars) shRNA and further selected 
by puromycin for 48 hours. The expression level of the indicated genes was determined by 
qRT-PCR. Samples were normalized against levels of Gapdh and the expression level of 
each gene in empty vector control cells was arbitrarily set to 1. (b) Total protein was 
collected from cells prepared as in (a) and subjected to Western Blot analysis using 
antibodies against p15Ink4b, p16Ink4a, p21 and tublin. (c) Primary MEF cells isolated from 
p15Ink4b null mice at passage 1 were transduced with lentiviral control (diamonds), Jhdm1b 
(Jhdm1b KD, squares), and Ring1b (Ring1b KD, triangles) shRNA and further selected by 
puromycin for 48 hours. 5×105 cells were plated and cell number was counted at different 
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time points using a hemocytometer. (d) Primary MEFs were prepared as in (c), pulse labeled 
with BrdU and stained with PI and FITC conjugated anti-BrdU antibody. The percentage of 
BrdU positive cells was determined by flow cytometry for control (black bars), Jhdm1b KD 
(grey bars) and Ring1b KD (empty bars). All error bars represent s.d. (n=3).
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Figure 4. Jhdm1b regulates cell proliferation and p15Ink4b expression in a histone demethylase 
activity-dependent manner
(a) Primary MEF cells were transduced with lentiviral vectors carrying control shRNA 
(diamonds), Jhdm1b shRNA (Jhdm1b KD, squares), and Jhdm1b shRNA with expression of 
F-Jhdm1b (Jhdm1b KD/F-Jhdm1b, circles) or F-Jhdm1b(H211A) (triangles). 5×105 cells 
were plated 48 hours after transduction and maintained in culture for 8 days. Cell number 
was counted using a hemocytometer at the indicated time points. (b) mRNA was collected 
from cells prepared as in (a) and qRT-PCR was carried out to determine p15Ink4a expression 
level in each sample. Samples were normalized against levels of Gapdh and the expression 
level of each gene in empty vector control cells was arbitrarily set to 1. (c) Schematic 
representation of the p15Ink4b locus in mouse indicating the genomic structure of the locus 
(exons demarcated by black boxes), as well as the location of the three amplicons studied in 
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ChIP experiments. (d) ChIP experiment utilizing chromatin prepared from primary MEF 
cells transduced with retrovirus encoding F-Jhdm1b (empty bars) or control virus (black 
bars) were carried out using antibody against Flag. F-Jhdm1b binding was assayed via qPCR 
at the three genomic regions depicted in (c). (e) ChIP experiment utilizing chromatin from 
primary MEFs prepared as in (a) was carried out using antibody specific for H3K36me2. 
H3K36me2 levels were assayed via qPCR at the three genomic regions depicted in (c). Error 
bars represent s.d. (n=3).
He et al. Page 19













Figure 5. Jhdm1b facilitates Ras induced neoplastic transformation
(a) Primary MEF cells were transduced with mock or F-Jhdm1b expressing lentiviral vector 
followed by superinfection with retroviral H-Ras12V. 5000 cells were plated on soft agar 
and analyzed 14 days later. Graph represents quantification of large colonies on H-Ras 
transduced plates. (b) Primary MEF cells were transduced with lentiviral vectors carrying 
control shRNA (Control shRNA) or Jhdm1b shRNA (Jhdm1b KD) followed by puromycin 
selection and retroviral H-Ras12V transduction. 5000 cells were plated on soft agar and 
analyzed 14 days later. Graph represents quantification of large colonies on H-Ras 
transduced plates. All error bars represent s.d. (n=3).
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